{
    "name": "timolol/brimonidine",
    "comment": "Rx",
    "other_names": [
        "Combigan"
    ],
    "classes": [
        "Antiglaucoma",
        "Combos"
    ],
    "source": "https://reference.medscape.com/drug/combigan-timolol-brimonidine-343610",
    "pregnancy": {
        "common": [
            "There are no adequate and well-controlled studies in pregnant women; however, in animal studies, brimonidine crossed the placenta and entered into the fetal circulation to a limited extent; because animal reproduction studies are not always predictive of human response, this drug combination should be used during pregnancy only if potential benefit to mother justifies potential risk to fetus",
            "Teratogenicity studies have been performed in animals; brimonidine tartrate was not teratogenic when given orally during gestation days 6 through 15 in rats and days 6 through 18 in rabbits; the highest doses of brimonidine tartrate in rats (2.5 mg/kg/day) and rabbits (5 mg/kg/day) achieved AUC exposure values 580 and37-fold higher, respectively than similar values estimated in humans treated with this drug combination, 1 drop in both eyes twice daily",
            "Teratogenicity studies with timolol in mice, rats, and rabbits at oral doses up to 50 mg/kg/day [4,200 times maximum recommended human ocular dose of 0.012 mg/kg/day on a mg/kg basis (MRHOD)] demonstrated no evidence of fetal malformations; although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring; doses of 1,000 mg/kg/day (83,000 times the MRHOD) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses 8,300 times the MRHOD without apparent maternotoxicity"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Timolol has been detected in human milk following oral and ophthalmic drug administration; it is not known whether brimonidine tartrate is excreted in human milk, although in animal studies, brimonidine tartrate has been shown to be excreted in breast milk; because of potential for serious adverse reactions from this drug combination in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity to either product or other components",
                "Reactive airway disease, including severe COPD or active or history of bronchial asthma",
                "Sinus bradycardia, 2°/3° AV block, overt cardiac failure, cardiogenic shock",
                "Neonates and infants (<2 years)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Not to be used alone for acute angle-closure glaucoma",
                "Remove soft contact lenses; may reinsert 15 min post-instillation",
                "May potentiate syndromes associated with vascular insufficiency; this drug combination should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud’s phenomenon, orthostatic hypotension, or thromboangiitis obliterans",
                "While taking beta-blockers, patients with history of atopy or history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens; such patients may be unresponsive to usual doses of epinephrine used to treat anaphylactic reactions",
                "Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (eg, diplopia, ptosis, and generalized weakness); timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms",
                "Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients (especially those with labile diabetes) who are receiving insulin or oral hypoglycemic agents; beta-adrenergic receptor blocking agents may mask signs and symptoms of acute hypoglycemia",
                "Beta-adrenergic blocking agents may mask certain clinical signs (eg, tachycardia) of hyperthyroidism; patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta­ adrenergic blocking agents that might precipitate a thyroid storm",
                "Ocular hypersensitivity reactions reported with brimonidine tartrate ophthalmic solutions 0.2%, with some reported to be associated with increase in intraocular pressure",
                "There have been reports of bacterial keratitis associated with use of multiple-dose containers of topical ophthalmic products; these containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of ocular epithelial surface"
            ],
            "specific": [
                {
                    "type": "Impairment of beta-adrenergically mediated reflexes",
                    "description": [
                        "Necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial; beta-adrenergic receptor blockade impairs ability of heart to respond to beta­adrenergically mediated reflex stimuli; this may augment risk of general anesthesia in surgical procedures",
                        "Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe hypotension during anesthesia; difficulty in restarting and maintaining heartbeat also reported; for these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta­ adrenergic receptor blocking agent",
                        "If necessary, during surgery, effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists"
                    ]
                },
                {
                    "type": "Respiratory and cardiac reactions",
                    "description": [
                        "Can be absorbed systemically; the same types of adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration",
                        "Severe respiratory reactions and cardiac reactions including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure reported with ophthalmic administration; ophthalmic beta-blockers may impair compensatory tachycardia and increase risk of hypotension",
                        "Sympathetic stimulation may be essential for support of circulation in individuals with diminished myocardial contractility; its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure",
                        "In patients without history of cardiac failure, continued depression of myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure; at first sign or symptom of cardiac failure, therapy should be discontinued",
                        "Patients with chronic obstructive pulmonary disease (eg, chronic bronchitis, emphysema) of mild or moderate severity, bronchospastic disease, or a history of the bronchospastic disease (other than bronchial asthma or a history of bronchial asthma, in which this drug combination is contraindicated should, in general, not receive beta-blocking agents, including this product"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "isocarboxazid, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "linezolid",
            "description": {
                "common": "linezolid, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenelzine",
            "description": {
                "common": "phenelzine, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "procarbazine",
            "description": {
                "common": "procarbazine, brimonidine. Mechanism: unknown. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rasagiline",
            "description": {
                "common": "rasagiline, brimonidine. Mechanism: unknown. Contraindicated. Brimonidine should not be used in patients receiving MAO inhibitors."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "selegiline",
            "description": {
                "common": "selegiline, brimonidine. Mechanism: unknown. Contraindicated. Coadministration is contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "selegiline transdermal",
            "description": {
                "common": "selegiline transdermal, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "tranylcypromine, brimonidine. Mechanism: unknown. Contraindicated. Contraindicated in mfr prescribing info."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "acebutolol",
            "description": {
                "common": "acebutolol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "artemether/lumefantrine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atenolol",
            "description": {
                "common": "atenolol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "betaxolol",
            "description": {
                "common": "betaxolol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "bisoprolol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carvedilol",
            "description": {
                "common": "carvedilol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "celiprolol",
            "description": {
                "common": "celiprolol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clonidine",
            "description": {
                "common": "clonidine, timolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dacomitinib",
            "description": {
                "common": "dacomitinib will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "digoxin",
            "description": {
                "common": "digoxin, timolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diltiazem",
            "description": {
                "common": "diltiazem, timolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "epinephrine",
            "description": {
                "common": "timolol increases effects of epinephrine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "epinephrine racemic",
            "description": {
                "common": "timolol increases effects of epinephrine racemic by pharmacodynamic synergism. Avoid or Use Alternate Drug. Risk of hypertension and bradycardia.  Consider selective beta 1 blocker (e.g., metoprolol)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "esmolol",
            "description": {
                "common": "esmolol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "fexinidazole, timolol.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to induce bradycardia.  ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "fluoxetine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "givosiran",
            "description": {
                "common": "givosiran will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iobenguane I 131",
            "description": {
                "common": "timolol will decrease the level or effect of iobenguane I 131 by  Other (see comment). Avoid or Use Alternate Drug. Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Do not administer these drugs until at least 7 days after each iobenguane dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "labetalol",
            "description": {
                "common": "labetalol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lofexidine",
            "description": {
                "common": "lofexidine, timolol.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that decrease pulse or blood pressure to mitigate risk of excessive bradycardia and hypotension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lumefantrine",
            "description": {
                "common": "lumefantrine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mavacamten",
            "description": {
                "common": "timolol, mavacamten.\nEither increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Expect additive negative inotropic effects of mavacamten and other drugs that reduce cardiac contractility."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoprolol",
            "description": {
                "common": "metoprolol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nadolol",
            "description": {
                "common": "nadolol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nebivolol",
            "description": {
                "common": "nebivolol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "paroxetine",
            "description": {
                "common": "paroxetine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "penbutolol",
            "description": {
                "common": "penbutolol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pindolol",
            "description": {
                "common": "pindolol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "propranolol",
            "description": {
                "common": "propranolol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quinidine",
            "description": {
                "common": "quinidine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rivastigmine",
            "description": {
                "common": "timolol increases toxicity of rivastigmine by pharmacodynamic synergism. Avoid or Use Alternate Drug. Additive bradycardia effect may result in syncope."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sotalol",
            "description": {
                "common": "sotalol and timolol both increase  anti-hypertensive channel blocking. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "umeclidinium bromide/vilanterol inhaled",
            "description": {
                "common": "timolol, umeclidinium bromide/vilanterol inhaled. pharmacodynamic antagonism. Avoid or Use Alternate Drug. If a  beta-blocker must be used in patients with COPD taking a beta-agonist, consider using a beta-blocker that is  beta-1 selective ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "verapamil",
            "description": {
                "common": "verapamil, timolol.\nEither increases toxicity of the other by unspecified interaction mechanism. Avoid or Use Alternate Drug. Can increase risk of bradycardia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vilanterol/fluticasone furoate inhaled",
            "description": {
                "common": "timolol, vilanterol/fluticasone furoate inhaled. pharmacodynamic antagonism. Avoid or Use Alternate Drug. If a  beta-blocker must be used in patients with COPD taking a beta-agonist, consider using a beta-blocker that is  beta-1 selective ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acebutolol",
            "description": {
                "common": "acebutolol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aceclofenac",
            "description": {
                "common": "timolol and aceclofenac both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acemetacin",
            "description": {
                "common": "timolol and acemetacin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acrivastine",
            "description": {
                "common": "acrivastine and brimonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albuterol",
            "description": {
                "common": "timolol increases and albuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aldesleukin",
            "description": {
                "common": "aldesleukin increases effects of timolol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "alfuzosin and timolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aluminum hydroxide",
            "description": {
                "common": "aluminum hydroxide decreases levels of timolol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amifostine",
            "description": {
                "common": "amifostine, brimonidine.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. When amifostine is used at chemotherapeutic doses, withhold blood pressure lowering medications for 24 hr prior to amifostine; if blood pressure lowering medication cannot be withheld, do not administer amifostine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiloride",
            "description": {
                "common": "timolol and amiloride both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amisulpride",
            "description": {
                "common": "amisulpride and brimonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "amiodarone will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amlodipine",
            "description": {
                "common": "timolol and amlodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital decreases levels of timolol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of amobarbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "arformoterol",
            "description": {
                "common": "timolol increases and arformoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "articaine",
            "description": {
                "common": "timolol, articaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine",
            "description": {
                "common": "asenapine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "asenapine transdermal",
            "description": {
                "common": "asenapine transdermal and brimonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin",
            "description": {
                "common": "timolol and aspirin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin rectal",
            "description": {
                "common": "timolol and aspirin rectal both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aspirin/citric acid/sodium bicarbonate",
            "description": {
                "common": "aspirin/citric acid/sodium bicarbonate decreases effects of timolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir increases effects of timolol by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of hypotension, bradycardia, AV block, and prolonged PR interval. Consider lowering beta blocker dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atenolol",
            "description": {
                "common": "atenolol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avanafil",
            "description": {
                "common": "avanafil increases effects of timolol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "avapritinib and brimonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "timolol increases and bendroflumethiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "benzhydrocodone/acetaminophen and brimonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betaxolol",
            "description": {
                "common": "betaxolol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bismuth subsalicylate",
            "description": {
                "common": "bismuth subsalicylate, timolol. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Blockage of renal prostaglandin synthesis; may cause severe hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "bisoprolol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bretylium",
            "description": {
                "common": "timolol, bretylium.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Each drug may cause hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "brexpiprazole and brimonidine both increase  sedation. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bumetanide",
            "description": {
                "common": "timolol increases and bumetanide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupivacaine",
            "description": {
                "common": "timolol, bupivacaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Use extreme caution during concomitant use of bupivacaine and antihypertensive agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupropion",
            "description": {
                "common": "bupropion will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital decreases levels of timolol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of butabarbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital decreases levels of timolol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of butalbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium acetate",
            "description": {
                "common": "calcium acetate decreases effects of timolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium carbonate",
            "description": {
                "common": "calcium carbonate decreases effects of timolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium chloride",
            "description": {
                "common": "calcium chloride decreases effects of timolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium citrate",
            "description": {
                "common": "calcium citrate decreases effects of timolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcium gluconate",
            "description": {
                "common": "calcium gluconate decreases effects of timolol by unspecified interaction mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "candesartan",
            "description": {
                "common": "timolol, candesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbenoxolone",
            "description": {
                "common": "timolol increases and carbenoxolone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "brimonidine increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbidopa",
            "description": {
                "common": "carbidopa increases effects of timolol by pharmacodynamic synergism. Use Caution/Monitor. Therapy with carbidopa, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of the antihypertensive drug may be required."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "carvedilol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celecoxib",
            "description": {
                "common": "celecoxib will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "celiprolol",
            "description": {
                "common": "celiprolol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloroprocaine",
            "description": {
                "common": "timolol, chloroprocaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chloroquine",
            "description": {
                "common": "chloroquine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "timolol increases and chlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "timolol decreases effects of chlorpropamide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "timolol increases and chlorthalidone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "choline magnesium trisalicylate",
            "description": {
                "common": "timolol and choline magnesium trisalicylate both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "citalopram increases levels of timolol by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clevidipine",
            "description": {
                "common": "timolol and clevidipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonidine",
            "description": {
                "common": "timolol, clonidine. Mechanism: pharmacodynamic synergism. Modify Therapy/Monitor Closely. Non selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "timolol increases and cyclopenthiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darifenacin",
            "description": {
                "common": "darifenacin will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dasiglucagon",
            "description": {
                "common": "timolol decreases effects of dasiglucagon by unknown mechanism. Use Caution/Monitor. Dasiglucagon may stimulate catecholamine release; whereas beta blockers may inhibit catecholamines released in response to dasiglucagon. Coadministration may also transiently increase pulse and BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desflurane",
            "description": {
                "common": "desflurane, timolol.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desvenlafaxine",
            "description": {
                "common": "desvenlafaxine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Desvenlafaxine inhibits CYP2D6; with higher desvenlafaxine doses (ie, 400 mg) decrease the CYP2D6 substrate dose by up to 50%; no dosage adjustment needed with desvenlafaxine doses <100 mg"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diclofenac",
            "description": {
                "common": "timolol and diclofenac both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diflunisal",
            "description": {
                "common": "timolol and diflunisal both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "timolol and digoxin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diltiazem",
            "description": {
                "common": "timolol and diltiazem both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "diphenhydramine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dobutamine",
            "description": {
                "common": "timolol increases and dobutamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dopexamine",
            "description": {
                "common": "timolol increases and dopexamine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxazosin",
            "description": {
                "common": "doxazosin and timolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronedarone",
            "description": {
                "common": "dronedarone will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "drospirenone",
            "description": {
                "common": "timolol and drospirenone both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duloxetine",
            "description": {
                "common": "duloxetine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eliglustat",
            "description": {
                "common": "eliglustat increases levels of timolol by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the concomitant drug and titrate to clinical effect."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of timolol by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Cobicistat is a CYP2D6 inhibitor; caution with CYP2D6 substrates for which elevated plasma concentrations are associated with serious and/or life-threatening events."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ephedrine",
            "description": {
                "common": "timolol increases and ephedrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine",
            "description": {
                "common": "timolol increases and epinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine inhaled",
            "description": {
                "common": "timolol decreases effects of epinephrine inhaled by pharmacodynamic antagonism. Use Caution/Monitor. Beta2-adrenergic blockers may may inhibit bronchodilatory effects of epinephrine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "epinephrine racemic",
            "description": {
                "common": "timolol increases and epinephrine racemic decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eprosartan",
            "description": {
                "common": "timolol, eprosartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esketamine intranasal",
            "description": {
                "common": "esketamine intranasal, brimonidine.\nEither increases toxicity of the other by sedation. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "esmolol",
            "description": {
                "common": "esmolol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethacrynic acid",
            "description": {
                "common": "timolol increases and ethacrynic acid decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ether",
            "description": {
                "common": "timolol, ether.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Both beta blockers and ether depress the myocardium; consider lowering beta blocker dose if ether used for anesthesia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etodolac",
            "description": {
                "common": "timolol and etodolac both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etomidate",
            "description": {
                "common": "etomidate, timolol.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP2D6 substrates as necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felodipine",
            "description": {
                "common": "timolol and felodipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenbufen",
            "description": {
                "common": "timolol and fenbufen both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fenoprofen",
            "description": {
                "common": "timolol and fenoprofen both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fingolimod",
            "description": {
                "common": "timolol increases effects of fingolimod by pharmacodynamic synergism. Use Caution/Monitor. Both medications decrease heart rate. Monitor patients on concomitant therapy, particularly in the first 6 hours after fingolimod is initiated or after a treatment interruption of at least two weeks,  for bradycardia and atrioventricular block. To identify underlying risk factors of bradycardia and AV block, obtain a new or recent ECG in patients using beta-blockers prior to starting fingolimod."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "timolol and flurbiprofen both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "formoterol",
            "description": {
                "common": "timolol increases and formoterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "furosemide",
            "description": {
                "common": "timolol increases and furosemide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gentamicin",
            "description": {
                "common": "timolol increases and gentamicin decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "timolol decreases effects of glimepiride by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "timolol decreases effects of glipizide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glucagon",
            "description": {
                "common": "glucagon decreases toxicity of timolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glucagon intranasal",
            "description": {
                "common": "glucagon intranasal decreases toxicity of timolol by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. Coadministration of glucagon with beta-blockers may have transiently increased pulse and blood pressure."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "timolol decreases effects of glyburide by pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers may also mask the symptoms of hypoglycemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "guanfacine",
            "description": {
                "common": "timolol, guanfacine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Non selective beta blocker administration during withdrawal from centrally acting alpha agonists may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydralazine",
            "description": {
                "common": "hydralazine increases effects of timolol by pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "timolol increases and hydrochlorothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "timolol and ibuprofen both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "ibuprofen IV decreases effects of timolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imatinib",
            "description": {
                "common": "imatinib will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indacaterol, inhaled",
            "description": {
                "common": "indacaterol, inhaled, timolol. Other (see comment). Use Caution/Monitor. \nComment: Beta-blockers and indacaterol may interfere with the effect of each other when administered concurrently. Beta-blockers may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indapamide",
            "description": {
                "common": "timolol increases and indapamide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indomethacin",
            "description": {
                "common": "timolol and indomethacin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "timolol, insulin aspart. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "timolol, insulin degludec. Other (see comment). Modify Therapy/Monitor Closely. \nComment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "timolol, insulin degludec/insulin aspart. Other (see comment). Modify Therapy/Monitor Closely. \nComment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "timolol, insulin detemir. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "timolol, insulin glargine. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "timolol, insulin glulisine. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "timolol, insulin inhaled. Other (see comment). Modify Therapy/Monitor Closely. \nComment: Beta-blockers may either increase or decrease the blood glucose lowering effect of insulin; beta-blockers can prolong hypoglycemia (interference with glycogenolysis) or cause hyperglycemia (insulin secretion inhibited)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "timolol, insulin lispro. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "timolol, insulin NPH. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "timolol, insulin regular human. Mechanism: pharmacodynamic antagonism. Use Caution/Monitor. Non selective beta blockers delay recovery of normoglycemia after insulin induced hypoglycemia; however, they also inhibit insulin secretion, so long term beta blocker Tx may result in reduced glucose tolerance.  Insulin induced hypoglycemia may induce hypertension during non selective beta blocker Tx."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "irbesartan",
            "description": {
                "common": "timolol, irbesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoproterenol",
            "description": {
                "common": "timolol increases and isoproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "lasmiditan, brimonidine.\nEither increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isradipine",
            "description": {
                "common": "timolol and isradipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivabradine",
            "description": {
                "common": "ivabradine, timolol.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Most patients receiving ivabradine will also be treated with a beta-blocker. The risk of bradycardia increases with  coadministration of drugs that slow heart rate (eg, digoxin, amiodarone, beta-blockers). Monitor heart rate in patients taking ivabradine with other negative chronotropes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketamine",
            "description": {
                "common": "ketamine, timolol.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketoprofen",
            "description": {
                "common": "timolol and ketoprofen both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac",
            "description": {
                "common": "timolol and ketorolac both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketorolac intranasal",
            "description": {
                "common": "timolol and ketorolac intranasal both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "labetalol",
            "description": {
                "common": "labetalol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lasmiditan",
            "description": {
                "common": "timolol increases effects of lasmiditan by pharmacodynamic synergism. Use Caution/Monitor. Lasmiditan has been associated with a lowering of heart rate (HR). In a drug interaction study, addition of a single 200-mg dose of lasmiditan to propranolol decreased HR by an additional 5 bpm compared to propranolol alone, for a mean maximum of 19 bpm."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levalbuterol",
            "description": {
                "common": "timolol increases and levalbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levodopa",
            "description": {
                "common": "levodopa increases effects of timolol by pharmacodynamic synergism. Use Caution/Monitor. Consider decreasing dosage of antihypertensive agent."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lidocaine",
            "description": {
                "common": "timolol, lidocaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Increased effects of epinephrine in anesthetic; risk of hypertension and bradycardia.  Do NOT D/C chronic beta blocker Tx prior to anesthetic administration.  Consider selective beta 1 blocker (e.g., metoprolol)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir increases levels of timolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of PR prolongation and cardiac arrhythmias. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lorcaserin",
            "description": {
                "common": "lorcaserin will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lornoxicam",
            "description": {
                "common": "timolol and lornoxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "losartan and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone, brimonidine.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Potential for increased CNS depressant effects when used concurrently; monitor for increased sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maraviroc",
            "description": {
                "common": "maraviroc will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin rectal",
            "description": {
                "common": "nitroglycerin rectal, brimonidine.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Observe for possible additive hypotensive effects during concomitant use. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "marijuana",
            "description": {
                "common": "marijuana will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meclofenamate",
            "description": {
                "common": "meclofenamate decreases effects of timolol by pharmacodynamic antagonism. Use Caution/Monitor. Long term (>1 wk) NSAID use.  NSAIDs decrease prostaglandin synthesis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefenamic acid",
            "description": {
                "common": "timolol and mefenamic acid both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mefloquine",
            "description": {
                "common": "mefloquine increases levels of timolol by decreasing metabolism. Use Caution/Monitor. Risk of arrhythmia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meloxicam",
            "description": {
                "common": "timolol and meloxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mepivacaine",
            "description": {
                "common": "timolol, mepivacaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Use extreme caution during concomitant use of bupivacaine and antihypertensive agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metaproterenol",
            "description": {
                "common": "timolol increases and metaproterenol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "timolol increases and methyclothiazide decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor.  ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyldopa",
            "description": {
                "common": "timolol, methyldopa. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Non selective beta blocker administration during withdrawal from methyldopa may result in rebound hypertension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylphenidate",
            "description": {
                "common": "methylphenidate will decrease the level or effect of timolol by  pharmacodynamic antagonism. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metolazone",
            "description": {
                "common": "timolol increases and metolazone decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "metoprolol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirabegron",
            "description": {
                "common": "mirabegron will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxisylyte",
            "description": {
                "common": "moxisylyte and timolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nabumetone",
            "description": {
                "common": "timolol and nabumetone both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nadolol",
            "description": {
                "common": "nadolol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naproxen",
            "description": {
                "common": "timolol and naproxen both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nebivolol",
            "description": {
                "common": "nebivolol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "timolol and nicardipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nifedipine",
            "description": {
                "common": "timolol and nifedipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nilotinib",
            "description": {
                "common": "nilotinib will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "timolol and nisoldipine both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitroglycerin rectal",
            "description": {
                "common": "nitroglycerin rectal, timolol.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Beta-blockers blunt the reflex tachycardia produced by nitroglycerin without preventing its hypotensive effects. If beta-blockers are used with nitroglycerin in patients with angina pectoris, additional hypotensive effects may occur."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "norepinephrine",
            "description": {
                "common": "timolol increases and norepinephrine decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olmesartan",
            "description": {
                "common": "timolol, olmesartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "olodaterol inhaled",
            "description": {
                "common": "timolol, olodaterol inhaled.\nEither decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor. Beta-blockers and olodaterol may interfere with the effect of each other when administered concurrently. Beta-blockers may produce severe bronchospasm in COPD patients. Therefore, patients with COPD should not normally be treated with beta-blockers. However, under certain circumstances, e.g. as prophylaxis after myocardial infarction, there may be no acceptable alternatives to the use of beta-blockers in patients with COPD. In this setting, cardioselective beta-blockers could be considered, although they should be administered with caution."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "brimonidine increases effects of sacubitril/valsartan by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxaprozin",
            "description": {
                "common": "timolol and oxaprozin both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxymetazoline intranasal",
            "description": {
                "common": "timolol increases effects of oxymetazoline intranasal by pharmacodynamic synergism. Use Caution/Monitor. When beta-2 receptors are antagonized by nonselective beta blockers, alpha1 vasoconstriction may be unopposed, thus increasing hypertensive effect. When oxymetazoline is combined with intranasal tetracaine for dental anesthesia, avoid or use an alternant anesthetic in patients taking nonselective beta blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxymetazoline topical",
            "description": {
                "common": "oxymetazoline topical increases and timolol decreases sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "parecoxib",
            "description": {
                "common": "parecoxib will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "peginterferon alfa 2b",
            "description": {
                "common": "peginterferon alfa 2b, timolol. Other (see comment). Use Caution/Monitor. \nComment: When patients are administered peginterferon alpha-2b with CYP2D6 substrates, the therapeutic effect of these drugs may be altered. Peginterferon alpha-2b may increase or decrease levels of CYP2D6 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "penbutolol",
            "description": {
                "common": "penbutolol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital decreases levels of timolol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of pentobarbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "perphenazine",
            "description": {
                "common": "perphenazine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital decreases levels of timolol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of phenobarbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenoxybenzamine",
            "description": {
                "common": "phenoxybenzamine and timolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phentolamine",
            "description": {
                "common": "phentolamine and timolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenylephrine",
            "description": {
                "common": "timolol increases effects of phenylephrine by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode (rare)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenylephrine PO",
            "description": {
                "common": "timolol increases effects of phenylephrine PO by pharmacodynamic synergism. Use Caution/Monitor. Risk of acute hypertensive episode (rare)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pindolol",
            "description": {
                "common": "pindolol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pirbuterol",
            "description": {
                "common": "timolol increases and pirbuterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "piroxicam",
            "description": {
                "common": "timolol and piroxicam both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ponesimod",
            "description": {
                "common": "ponesimod and timolol both increase  pharmacodynamic synergism. Use Caution/Monitor. Beta-blockers may have additive effects on lowering HR. Consider resting HR before initiating ponesimod in patients on stable dose of beta-blocker. Refer to the ponesimod prescribing information for more dosing information."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium acid phosphate",
            "description": {
                "common": "timolol and potassium acid phosphate both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium chloride",
            "description": {
                "common": "timolol and potassium chloride both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "potassium citrate",
            "description": {
                "common": "timolol and potassium citrate both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prazosin",
            "description": {
                "common": "prazosin and timolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prilocaine",
            "description": {
                "common": "timolol, prilocaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Use extreme caution during concomitant use of bupivacaine and antihypertensive agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone decreases levels of timolol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of primidone.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propafenone",
            "description": {
                "common": "propafenone will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propofol",
            "description": {
                "common": "propofol, timolol.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propranolol",
            "description": {
                "common": "propranolol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinacrine",
            "description": {
                "common": "quinacrine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ranolazine",
            "description": {
                "common": "ranolazine will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir increases levels of timolol by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of hypotension, bradycardia, AV block, and prolonged PR interval. Consider lowering beta blocker dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rolapitant",
            "description": {
                "common": "rolapitant will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor. Rolapitant may increase plasma concentrations of CYP2D6 substrates for at least 28 days following rolapitant administration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ropivacaine",
            "description": {
                "common": "timolol, ropivacaine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Use extreme caution during concomitant use of bupivacaine and antihypertensive agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sacubitril/valsartan",
            "description": {
                "common": "sacubitril/valsartan and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salicylates (non-asa)",
            "description": {
                "common": "timolol and salicylates (non-asa) both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salmeterol",
            "description": {
                "common": "timolol increases and salmeterol decreases serum potassium. Effect of interaction is not clear, use caution. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "salsalate",
            "description": {
                "common": "timolol and salsalate both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir, timolol.\nEither increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Use alternatives if available. Increased risk of PR prolongation and cardiac arrhythmias."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital decreases levels of timolol by increasing metabolism. Use Caution/Monitor. Consider a higher beta-blocker dose during coadministration of secobarbital.  Atenolol, sotalol, nadolol less likely to be affected than other beta blockers."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "sertraline will increase the level or effect of timolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "sevoflurane, timolol.\nEither increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sildenafil",
            "description": {
                "common": "timolol increases effects of sildenafil by additive vasodilation. Use Caution/Monitor. Sildenafil has systemic vasodilatory properties and may further lower blood pressure in patients taking antihypertensive medications. Monitor blood pressure response to sildenafil in patients receiving concurrent blood pressure lowering therapy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "silodosin",
            "description": {
                "common": "silodosin and timolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "siponimod",
            "description": {
                "common": "siponimod, timolol.\nEither increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Caution when siponimod is initiated in patients receiving beta-blocker treatment because of additive effects on lowering heart rate. Temporary interruption of beta-blocker may be needed before initiating siponimod. Beta-blocker treatment can be initiated in patients receiving stable doses of siponimod."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium bicarbonate",
            "description": {
                "common": "sodium bicarbonate decreases levels of timolol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sodium citrate/citric acid",
            "description": {
                "common": "sodium citrate/citric acid decreases levels of timolol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sotalol",
            "description": {
                "common": "sotalol and timolol both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "spironolactone",
            "description": {
                "common": "timolol and spironolactone both increase  serum potassium. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, brimonidine.\nEither increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "succinylcholine",
            "description": {
                "common": "timolol and succinylcholine both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulfasalazine",
            "description": {
                "common": "timolol and sulfasalazine both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sulindac",
            "description": {
                "common": "timolol and sulindac both increase  serum potassium. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tadalafil",
            "description": {
                "common": "tadalafil increases effects of timolol by pharmacodynamic synergism. Use Caution/Monitor. Risk of hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "telmisartan",
            "description": {
                "common": "timolol, telmisartan. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Risk of fetal compromise if given during pregnancy."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terazosin",
            "description": {
                "common": "terazosin and timolol both increase  anti-hypertensive channel blocking. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valsartan",
            "description": {
                "common": "brimonidine increases effects of valsartan by pharmacodynamic synergism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acebutolol",
            "description": {
                "common": "brimonidine increases effects of acebutolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "adenosine",
            "description": {
                "common": "timolol, adenosine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "agrimony",
            "description": {
                "common": "agrimony increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alfentanil",
            "description": {
                "common": "brimonidine increases effects of alfentanil by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "brimonidine increases effects of alfuzosin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alprazolam",
            "description": {
                "common": "brimonidine increases effects of alprazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amiloride",
            "description": {
                "common": "brimonidine increases effects of amiloride by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "amitriptyline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amlodipine",
            "description": {
                "common": "brimonidine increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amobarbital",
            "description": {
                "common": "brimonidine increases effects of amobarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "amoxapine",
            "description": {
                "common": "amoxapine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "brimonidine increases effects of aripiprazole by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "asenapine",
            "description": {
                "common": "brimonidine increases effects of asenapine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "atenolol",
            "description": {
                "common": "brimonidine increases effects of atenolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "azelastine",
            "description": {
                "common": "brimonidine increases effects of azelastine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "belladonna and opium",
            "description": {
                "common": "brimonidine increases effects of belladonna and opium by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "benazepril",
            "description": {
                "common": "brimonidine increases effects of benazepril by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bendroflumethiazide",
            "description": {
                "common": "brimonidine increases effects of bendroflumethiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "benperidol",
            "description": {
                "common": "brimonidine increases effects of benperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "betaxolol",
            "description": {
                "common": "brimonidine increases effects of betaxolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bisoprolol",
            "description": {
                "common": "brimonidine increases effects of bisoprolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bosentan",
            "description": {
                "common": "brimonidine increases effects of bosentan by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "brimonidine",
            "description": {
                "common": "brimonidine increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "brompheniramine",
            "description": {
                "common": "brimonidine increases effects of brompheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bumetanide",
            "description": {
                "common": "brimonidine increases effects of bumetanide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "brimonidine increases effects of buprenorphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "brimonidine increases effects of buprenorphine buccal by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butabarbital",
            "description": {
                "common": "brimonidine increases effects of butabarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butalbital",
            "description": {
                "common": "brimonidine increases effects of butalbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "butorphanol",
            "description": {
                "common": "brimonidine increases effects of butorphanol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "captopril",
            "description": {
                "common": "brimonidine increases effects of captopril by pharmacodynamic synergism. Minor/Significance Unknown. Both drugs lower blood pressure. Monitor blood pressure."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carbinoxamine",
            "description": {
                "common": "brimonidine increases effects of carbinoxamine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "carvedilol",
            "description": {
                "common": "brimonidine increases effects of carvedilol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "celiprolol",
            "description": {
                "common": "brimonidine increases effects of celiprolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cevimeline",
            "description": {
                "common": "cevimeline increases effects of timolol by unspecified interaction mechanism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chloral hydrate",
            "description": {
                "common": "brimonidine increases effects of chloral hydrate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlordiazepoxide",
            "description": {
                "common": "brimonidine increases effects of chlordiazepoxide by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorothiazide",
            "description": {
                "common": "brimonidine increases effects of chlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpheniramine",
            "description": {
                "common": "brimonidine increases effects of chlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "brimonidine increases effects of chlorpromazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlorthalidone",
            "description": {
                "common": "brimonidine increases effects of chlorthalidone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cinnarizine",
            "description": {
                "common": "brimonidine increases effects of cinnarizine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "ciprofloxacin increases levels of timolol by decreasing metabolism. Minor/Significance Unknown. May also rarely decrease beta blocker levels."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clemastine",
            "description": {
                "common": "brimonidine increases effects of clemastine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clevidipine",
            "description": {
                "common": "brimonidine increases effects of clevidipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clomipramine",
            "description": {
                "common": "clomipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clonazepam",
            "description": {
                "common": "brimonidine increases effects of clonazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clonidine",
            "description": {
                "common": "brimonidine increases effects of clonidine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clorazepate",
            "description": {
                "common": "brimonidine increases effects of clorazepate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clozapine",
            "description": {
                "common": "brimonidine increases effects of clozapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cocaine topical",
            "description": {
                "common": "timolol increases effects of cocaine topical by pharmacodynamic synergism. Minor/Significance Unknown. Risk of angina."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "codeine",
            "description": {
                "common": "brimonidine increases effects of codeine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cornsilk",
            "description": {
                "common": "cornsilk increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclizine",
            "description": {
                "common": "brimonidine increases effects of cyclizine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclopenthiazide",
            "description": {
                "common": "brimonidine increases effects of cyclopenthiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyproheptadine",
            "description": {
                "common": "brimonidine increases effects of cyproheptadine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "desipramine",
            "description": {
                "common": "desipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexchlorpheniramine",
            "description": {
                "common": "brimonidine increases effects of dexchlorpheniramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dexmedetomidine",
            "description": {
                "common": "brimonidine increases effects of dexmedetomidine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dextromoramide",
            "description": {
                "common": "brimonidine increases effects of dextromoramide by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diamorphine",
            "description": {
                "common": "brimonidine increases effects of diamorphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diazepam",
            "description": {
                "common": "brimonidine increases effects of diazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "difenoxin hcl",
            "description": {
                "common": "brimonidine increases effects of difenoxin hcl by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dihydroergotamine",
            "description": {
                "common": "dihydroergotamine, timolol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive vasospasm."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dihydroergotamine intranasal",
            "description": {
                "common": "dihydroergotamine intranasal, timolol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Additive vasospasm."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diltiazem",
            "description": {
                "common": "brimonidine increases effects of diltiazem by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dimenhydrinate",
            "description": {
                "common": "brimonidine increases effects of dimenhydrinate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diphenhydramine",
            "description": {
                "common": "brimonidine increases effects of diphenhydramine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diphenoxylate hcl",
            "description": {
                "common": "brimonidine increases effects of diphenoxylate hcl by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dipipanone",
            "description": {
                "common": "brimonidine increases effects of dipipanone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dipyridamole",
            "description": {
                "common": "dipyridamole, timolol. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxazosin",
            "description": {
                "common": "brimonidine increases effects of doxazosin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxepin",
            "description": {
                "common": "doxepin decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "doxylamine",
            "description": {
                "common": "brimonidine increases effects of doxylamine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "droperidol",
            "description": {
                "common": "brimonidine increases effects of droperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "drospirenone",
            "description": {
                "common": "brimonidine increases effects of drospirenone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "enalapril",
            "description": {
                "common": "brimonidine increases effects of enalapril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eplerenone",
            "description": {
                "common": "brimonidine increases effects of eplerenone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "epoprostenol",
            "description": {
                "common": "brimonidine increases effects of epoprostenol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "escitalopram",
            "description": {
                "common": "escitalopram increases levels of timolol by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "esmolol",
            "description": {
                "common": "brimonidine increases effects of esmolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "estazolam",
            "description": {
                "common": "brimonidine increases effects of estazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethacrynic acid",
            "description": {
                "common": "brimonidine increases effects of ethacrynic acid by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethanol",
            "description": {
                "common": "brimonidine increases effects of ethanol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "etomidate",
            "description": {
                "common": "brimonidine increases effects of etomidate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "felodipine",
            "description": {
                "common": "brimonidine increases effects of felodipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fenoldopam",
            "description": {
                "common": "fenoldopam increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown. Additive hypotensive effects."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "brimonidine increases effects of fluphenazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "forskolin",
            "description": {
                "common": "forskolin increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "flurazepam",
            "description": {
                "common": "brimonidine increases effects of flurazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosinopril",
            "description": {
                "common": "brimonidine increases effects of fosinopril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "furosemide",
            "description": {
                "common": "brimonidine increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "guanfacine",
            "description": {
                "common": "brimonidine increases effects of guanfacine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "haloperidol",
            "description": {
                "common": "brimonidine increases effects of haloperidol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydralazine",
            "description": {
                "common": "brimonidine increases effects of hydralazine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydrochlorothiazide",
            "description": {
                "common": "brimonidine increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydromorphone",
            "description": {
                "common": "brimonidine increases effects of hydromorphone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "hydroxyzine",
            "description": {
                "common": "brimonidine increases effects of hydroxyzine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iloperidone",
            "description": {
                "common": "brimonidine increases effects of iloperidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "iloprost",
            "description": {
                "common": "brimonidine increases effects of iloprost by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "imaging agents (gadolinium)",
            "description": {
                "common": "timolol, imaging agents (gadolinium). Mechanism: unknown. Minor/Significance Unknown. Increased risk of anaphylaxis from contrast media."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "imidapril",
            "description": {
                "common": "brimonidine increases effects of imidapril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "imipramine",
            "description": {
                "common": "imipramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "indapamide",
            "description": {
                "common": "brimonidine increases effects of indapamide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isradipine",
            "description": {
                "common": "brimonidine increases effects of isradipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ketanserin",
            "description": {
                "common": "brimonidine increases effects of ketanserin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "labetalol",
            "description": {
                "common": "brimonidine increases effects of labetalol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levobetaxolol",
            "description": {
                "common": "levobetaxolol increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levorphanol",
            "description": {
                "common": "brimonidine increases effects of levorphanol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lisinopril",
            "description": {
                "common": "brimonidine increases effects of lisinopril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lofepramine",
            "description": {
                "common": "lofepramine decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "loprazolam",
            "description": {
                "common": "brimonidine increases effects of loprazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lorazepam",
            "description": {
                "common": "brimonidine increases effects of lorazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "lormetazepam",
            "description": {
                "common": "brimonidine increases effects of lormetazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "loxapine",
            "description": {
                "common": "brimonidine increases effects of loxapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "brimonidine increases effects of loxapine inhaled by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maitake",
            "description": {
                "common": "maitake increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "maprotiline",
            "description": {
                "common": "maprotiline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "mecamylamine",
            "description": {
                "common": "brimonidine increases effects of mecamylamine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "melatonin",
            "description": {
                "common": "melatonin decreases toxicity of timolol by pharmacodynamic antagonism. Minor/Significance Unknown. Melatonin may correct beta blocker induced sleep disturbances."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meperidine",
            "description": {
                "common": "brimonidine increases effects of meperidine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meprobamate",
            "description": {
                "common": "brimonidine increases effects of meprobamate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methadone",
            "description": {
                "common": "brimonidine increases effects of methadone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "methyclothiazide",
            "description": {
                "common": "brimonidine increases effects of methyclothiazide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metipranolol ophthalmic",
            "description": {
                "common": "metipranolol ophthalmic increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metolazone",
            "description": {
                "common": "brimonidine increases effects of metolazone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metoprolol",
            "description": {
                "common": "brimonidine increases effects of metoprolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metyrosine",
            "description": {
                "common": "brimonidine increases effects of metyrosine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "midazolam",
            "description": {
                "common": "brimonidine increases effects of midazolam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "minoxidil",
            "description": {
                "common": "brimonidine increases effects of minoxidil by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "moexipril",
            "description": {
                "common": "brimonidine increases effects of moexipril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "morphine",
            "description": {
                "common": "brimonidine increases effects of morphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "moxisylyte",
            "description": {
                "common": "brimonidine increases effects of moxisylyte by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "moxonidine",
            "description": {
                "common": "brimonidine increases effects of moxonidine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nadolol",
            "description": {
                "common": "brimonidine increases effects of nadolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nalbuphine",
            "description": {
                "common": "brimonidine increases effects of nalbuphine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nebivolol",
            "description": {
                "common": "brimonidine increases effects of nebivolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "neostigmine",
            "description": {
                "common": "timolol, neostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nicardipine",
            "description": {
                "common": "brimonidine increases effects of nicardipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nifedipine",
            "description": {
                "common": "brimonidine increases effects of nifedipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "brimonidine increases effects of nisoldipine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "noni juice",
            "description": {
                "common": "timolol and noni juice both increase  serum potassium. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nortriptyline",
            "description": {
                "common": "nortriptyline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "octacosanol",
            "description": {
                "common": "octacosanol increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "olanzapine",
            "description": {
                "common": "brimonidine increases effects of olanzapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "opium tincture",
            "description": {
                "common": "brimonidine increases effects of opium tincture by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxazepam",
            "description": {
                "common": "brimonidine increases effects of oxazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxycodone",
            "description": {
                "common": "brimonidine increases effects of oxycodone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxymorphone",
            "description": {
                "common": "brimonidine increases effects of oxymorphone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paliperidone",
            "description": {
                "common": "brimonidine increases effects of paliperidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "papaveretum",
            "description": {
                "common": "brimonidine increases effects of papaveretum by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "penbutolol",
            "description": {
                "common": "brimonidine increases effects of penbutolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentazocine",
            "description": {
                "common": "brimonidine increases effects of pentazocine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "brimonidine increases effects of pentobarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "perindopril",
            "description": {
                "common": "brimonidine increases effects of perindopril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "perphenazine",
            "description": {
                "common": "brimonidine increases effects of perphenazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "brimonidine increases effects of phenobarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenoxybenzamine",
            "description": {
                "common": "brimonidine increases effects of phenoxybenzamine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phentolamine",
            "description": {
                "common": "brimonidine increases effects of phentolamine by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "physostigmine",
            "description": {
                "common": "timolol, physostigmine.\nEither increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive bradycardia."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pilocarpine",
            "description": {
                "common": "pilocarpine increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pimozide",
            "description": {
                "common": "brimonidine increases effects of pimozide by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pindolol",
            "description": {
                "common": "brimonidine increases effects of pindolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prazosin",
            "description": {
                "common": "brimonidine increases effects of prazosin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "primidone",
            "description": {
                "common": "brimonidine increases effects of primidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "brimonidine increases effects of prochlorperazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "promethazine",
            "description": {
                "common": "brimonidine increases effects of promethazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "propranolol",
            "description": {
                "common": "brimonidine increases effects of propranolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "protriptyline",
            "description": {
                "common": "protriptyline decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quazepam",
            "description": {
                "common": "brimonidine increases effects of quazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quetiapine",
            "description": {
                "common": "brimonidine increases effects of quetiapine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quinapril",
            "description": {
                "common": "brimonidine increases effects of quinapril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ramipril",
            "description": {
                "common": "brimonidine increases effects of ramipril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "reishi",
            "description": {
                "common": "reishi increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "risperidone",
            "description": {
                "common": "brimonidine increases effects of risperidone by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "secobarbital",
            "description": {
                "common": "brimonidine increases effects of secobarbital by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "shepherd's purse",
            "description": {
                "common": "shepherd's purse, timolol. Other (see comment). Minor/Significance Unknown. \nComment: Theoretically, shepherd's purse may interfere with BP control."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "silodosin",
            "description": {
                "common": "brimonidine increases effects of silodosin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sotalol",
            "description": {
                "common": "brimonidine increases effects of sotalol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "spironolactone",
            "description": {
                "common": "brimonidine increases effects of spironolactone by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sufentanil",
            "description": {
                "common": "brimonidine increases effects of sufentanil by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tapentadol",
            "description": {
                "common": "brimonidine increases effects of tapentadol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "temazepam",
            "description": {
                "common": "brimonidine increases effects of temazepam by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "terazosin",
            "description": {
                "common": "brimonidine increases effects of terazosin by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thioridazine",
            "description": {
                "common": "brimonidine increases effects of thioridazine by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "thiothixene",
            "description": {
                "common": "brimonidine increases effects of thiothixene by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "timolol",
            "description": {
                "common": "brimonidine increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tizanidine",
            "description": {
                "common": "tizanidine increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypotension."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "torsemide",
            "description": {
                "common": "brimonidine increases effects of torsemide by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tramadol",
            "description": {
                "common": "brimonidine increases effects of tramadol by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trandolapril",
            "description": {
                "common": "brimonidine increases effects of trandolapril by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "trazodone",
            "description": {
                "common": "trazodone decreases effects of brimonidine by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "treprostinil",
            "description": {
                "common": "treprostinil increases effects of timolol by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "triamterene",
            "description": {
                "common": "brimonidine increases effects of triamterene by pharmacodynamic synergism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "yohimbe",
            "description": {
                "common": "timolol decreases toxicity of yohimbe by pharmacodynamic antagonism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Allergic conjunctivitis",
            "percent": null
        },
        {
            "name": "Conjunctival folliculosis",
            "percent": null
        },
        {
            "name": "Conjunctival hyperemia",
            "percent": null
        },
        {
            "name": "Eye pruritus",
            "percent": null
        },
        {
            "name": "Ocular burning",
            "percent": null
        },
        {
            "name": "Stinging",
            "percent": null
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "Blepharitis",
            "percent": null
        },
        {
            "name": "Corneal erosion",
            "percent": null
        },
        {
            "name": "Depression",
            "percent": null
        },
        {
            "name": "Epiphora",
            "percent": null
        },
        {
            "name": "Eye discharge",
            "percent": null
        },
        {
            "name": "Eye dryness",
            "percent": null
        },
        {
            "name": "Eye irritation",
            "percent": null
        },
        {
            "name": "Eye pain",
            "percent": null
        },
        {
            "name": "Eyelid edema",
            "percent": null
        },
        {
            "name": "Eyelid erythema",
            "percent": null
        },
        {
            "name": "Eyelid pruritus",
            "percent": null
        },
        {
            "name": "Foreign body sensation",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Hypertension",
            "percent": null
        },
        {
            "name": "Oral dryness",
            "percent": null
        },
        {
            "name": "Somnolence",
            "percent": null
        },
        {
            "name": "Superficial punctate keratitis",
            "percent": null
        },
        {
            "name": "Visual disturbance",
            "percent": null
        }
    ]
}